Rockwell Medical Files NDA For Iron-Replacement Compound Triferic - Quick Facts

(RTTNews) - Rockwell Medical Technologies Inc. (RMTI), a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease, Monday announced the submission of a new drug application for Triferic, an iron-replacement compound for treating iron deficiency in chronic kidney disease patients who are receiving hemodialysis.

Triferic is meant to replace the 5 to 7 mg of iron lost during every dialysis treatment. The company said the unique iron compound has demonstrated the ability to effectively deliver sufficient iron to the bone marrow, maintain hemoglobin and not increase iron stores (ferritin), while significantly reducing ESA dose.